The CDSCO Panel rejects Nacto Pharma's request for a waiver of the Phase III CT for the anticancer erefitinib tablet.

Published Date: 14 Aug 2023

New Delhi: The Subject Expert Committee (SEC) has rejected the waiver of the proposed Phase III clinical trial for the dosages of 3 mg, 4 mg, and 5 mg of erlotinib tablets.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot